Latest From Viren Mehta
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.
Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish
As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses.
Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally
Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC.
Mehta Analysis: Who Will Speak Out As Regulators Are Politicized?
In his latest opinion piece, Viren Mehta fears the impact that ideologically motivated and protectionist actions around the world will have on the biopharma sector and ultimately on patients.
Mehta Analysis: What Can Tesla Teach Pharma?
The transformation of the automotive world has many lessons for biopharma, especially on the regulatory front, believes Viren Mehta of Mehta Partners.
Mehta Analysis: What Do Facebook Libra And Democrats At Presidential Debates Have In Common?
Viren Mehta of Mehta Partners LLC mulls the potential of blockchain, the rapidly evolving IT resource that secures every step in a business action.